SS Innovations International
Builds surgical robotics around the SSi Mantra platform.
Something off on this page? Send us feedback.
Profile
Sells the SSi Mantra surgical robotic system and SSi Mudra instruments. The India-based operating business, founded in 2019, became the core of the current Nasdaq-listed issuer through the CardioVentures merger.
SSi Mantra surgical robotic system and SSi Mudra instruments form the commercial offering of an India-based surgical-robotics business founded in 2019. Commercial sales began after the system's introduction, and the platform supports multiple surgical specialties.
R&D, manufacturing, assembly, and operations are concentrated in the Gurgaon/Delhi NCR area. The company states an affordability-and-accessibility objective for advanced surgical robotics.
The Florida-listed issuer took its current form through the CardioVentures merger and began Nasdaq trading as SSII in April 2025. Its listed identity reflects a merger-driven transition rather than a long-running U.S. medtech lineage.
Company facts
Key statistics
Year to date −37.8% · Average volume (30d) 61.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.01 | −$0.01 | 0.0% | $12.0M | $13.9M | +16.2% | +3.79% |
| May 13, 2026Q1 FY26 | — | −$0.02 | — | — | $11.1M | — | 0.00% |
| Mar 10, 2026Q4 FY25 | — | −$0.01 | — | — | $14.5M | — | +9.73% |
| Oct 28, 2025Q3 FY25 | — | −$0.02 | — | — | $12.8M | — | +1.53% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $10.0M | $12.8M | $14.5M | $11.1M | $13.9M | |
| Gross profit | $1.1M | $5.9M | $6.2M | $6.4M | $5.0M | $7.1M | |
| Operating income | −$5.9M | $97.0K | −$1.8M | −$735.0K | −$3.7M | −$2.3M | |
| Net income | −$5.7M | −$256.7K | −$3.7M | −$2.5M | −$3.6M | −$2.7M | |
| Diluted EPS | −$0.03 | −$0.00 | −$0.02 | −$0.01 | −$0.02 | −$0.01 | |
| Gross margin | 21.2% | 59.1% | 48.1% | 43.9% | 45.0% | 50.9% | |
| Operating margin | -115.6% | 1.0% | -14.3% | -5.1% | -33.0% | -16.3% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $4.7M · FY24 $21.2M · FY25 $42.5M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $13.6M · Total debt $3.2M · Total assets $97.0M · Shareholders' equity $53.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 200.13M · Float 7.73M · 3.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Srivastava Sudhir · director, 10 percent owner, officer: Chairman and CEO | 108.55M | 54.24% | Form 4 | Aug 14, 2026 |
| Frederic H. Moll · director, 10 percent owner: | 20.84M | 10.41% | Form 4 | Mar 10, 2026 |
| Ranjan R. Pai | 14.95M | 8.70% | 13G | Feb 12, 2025 |
| Manipal Global Health Services | 11.30M | 6.62% | 13G | Dec 2, 2024 |
| Barry F. Cohen · director, officer: COO - Americas | 7.76M | 3.87% | Form 4 | Jun 2, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 6, 2026 | Srivastava Sudhir | director, 10 percent owner, officer: Chairman and CEO | +498,753 | $4.01 |
| Mar 6, 2026 | Timothy P. Adams | director | +300,000 | $3.99 |
| Mar 6, 2026 | Frederic H. Moll | director, 10 percent owner: | +501,253 | $3.99 |
Peers
- Intuitive Surgical
da Vinci platforms span the same multi-specialty soft-tissue surgery.
- Medtronic
Hugo RAS extends into urologic, general, and gynecologic surgery.
- Johnson & Johnson
OTTAVA targets multi-specialty soft-tissue and upper-abdominal surgery.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SS Innovations International | $3.48 | −1.00% | $696.5M | — | — | 13.3 | +39.4% |
| Intuitive Surgical | $373.80 | +0.36% | $131.63B | 42.4 | 33.0 | 11.9 | +18.5% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 31.1 | 22.4 | 6.6 | +9.9% |